Eloxx Pharmaceuticals, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsEloxx Pharmaceuticals is a clinical-stage biopharmaceutical company developing exaluren, an oral small molecule designed to read through nonsense mutations, for rare kidney diseases.
What they do
Eloxx is developing exaluren (ERSG) to induce readthrough of premature stop codons caused by nonsense mutations so full-length proteins can be produced. Its lead program targets nonsense mutation Alport syndrome (NMAS), with a preclinical program in nonsense mutation ADPKD. It has exclusively licensed ZKN-013 to Almirall for rare skin diseases including RDEB and JEB.
Revenue drivers
- ZKN-013 license and milestones (Almirall) — Eloxx exclusively licensed ZKN-013 to Almirall and received a $3.0 million upfront payment plus a $3.0 million development milestone in 2024. It remains eligible for up to approximately $470.0 million in development and sales milestones and tiered royalties.
- Exaluren — The lead product candidate for NMAS and nmADPKD is clinical-stage and has not generated revenue; no product is approved.
Recent performance
2025 revenue was $0, and 2024 revenue of $6.4 million came from the Almirall payments, per reported annual figures. Full-year 2025 net loss was $6.0 million, or $(5.34) per diluted share, versus a $3.1 million net loss in 2024. For the three months ended June 30, 2026, net loss was $4.5 million, or $(0.39) per share, including $0.1 million of stock-based compensation. Cash and cash equivalents were $62.0 million at June 30, 2026, following a $66.0 million gross public offering; total liabilities were $17.2 million at December 31, 2025, with long-term debt of $0.
Strategy
Eloxx completed a June 2026 Nasdaq uplisting and a public offering of 2,975,000 shares and pre-funded warrants for 3,025,000 shares at $11.00 per share, for $66.0 million gross and $58.3 million net proceeds. It plans to initiate the Phase 2b NMAS trial in the third quarter of 2026, with topline data from the 16-week placebo-controlled portion by mid-2027 and final readout by end-2027. It also plans a Phase 2 nmADPKD trial in 2027, with topline data by mid-2028. Management states the $62.0 million cash balance should fund operations through the Alport syndrome and ADPKD data readouts.
Risks
- Filing delinquency — Eloxx could not file 10-Ks for 2023 and 2024 because it lacked sufficient resources, and there are no assurances it will regain or maintain Exchange Act compliance.
- Nasdaq history — Nasdaq suspended trading in Eloxx shares in October 2023 because it failed the $35 million market value of listed securities requirement; it now trades on the OTC Expert Market and has uplisted to Nasdaq, with no assurance of maintaining listing compliance.
- No approved product — Exaluren has not generated product revenue and remains dependent on clinical success of the Phase 2b NMAS trial and the planned Phase 2 nmADPKD trial.
- Cash needs — Eloxx has a history of operating losses, including a $6.0 million net loss in 2025 and a $4.5 million net loss in Q2 2026, and its $62.0 million cash balance is expected to fund operations only through the AS and ADPKD data readouts.
Outlook
Management expects to initiate the Phase 2b exaluren trial in NMAS in the third quarter of 2026, with topline data from the 16-week placebo-controlled portion by mid-2027 and final readout by end-2027. The Phase 2 nmADPKD trial is planned for 2027 with topline data by mid-2028. The company states the $62.0 million cash position, with no outstanding debt, funds operations through both readouts; Almirall remains responsible for ZKN-013 development.